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Abstract
α-Conotoxins preferentially antagonize muscle and neuronal nicotinic acetylcholine receptors (nAChRs).
Native α-conotoxins have two disulfide links, CI-CIII and CII-CIV, and owing to the inherent properties of
disulfide bonds, α-conotoxins have been systematically engineered to improve their chemical and biological
properties. In this study, we explored the possibility of simplifying the disulfide framework of α-conotoxins
Vc1.1, BuIA, ImI, and AuIB, by introducing [C2H,C8F] modification to the CI-CIII bond. We therefore
explored the possibility of using hydrophobic packing of standard amino acid side chains to replace disulfide
bonds as an alternative strategy to nonnatural amino acid cross-links. The impact of CI-CIII disulfide bond
replacement on the conformation of the α-conotoxins was investigated using molecular dynamics (MD)
simulations and nuclear magnetic resonance chemical shift index study. Two-electrode voltage clamp
techniques and MD simulations were used to study the impact of disulfide bond deletion on the activities of
the peptides at human neuronal nAChRs. All disulfide-deleted variants except ImI[C2H,C8F] had reduced
potency for inhibiting nAChRs. Our results suggest that the CI-CIII disulfide bond is important to stabilize
the secondary structure of α-conotoxins as well as their interaction with neuronal nAChR targets. Results
from this study enrich our understanding of the function of the CI-CIII disulfide bond and are useful in
guiding future structural engineering of the α-conotoxins.
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ABSTRACT: α-Conotoxins preferentially antagonize muscle
and neuronal nicotinic acetylcholine receptors (nAChRs).
Native α-conotoxins have two disulfide links, CI−CIII and CII−
CIV, and owing to the inherent properties of disulfide bonds, α-
conotoxins have been systematically engineered to improve
their chemical and biological properties. In this study, we
explored the possibility of simplifying the disulfide framework
of α-conotoxins Vc1.1, BuIA, ImI, and AuIB, by introducing
[C2H,C8F] modification to the CI−CIII bond. We therefore
explored the possibility of using hydrophobic packing of
standard amino acid side chains to replace disulfide bonds as
an alternative strategy to nonnatural amino acid cross-links.
The impact of CI−CIII disulfide bond replacement on the
conformation of the α-conotoxins was investigated using molecular dynamics (MD) simulations and nuclear magnetic resonance
chemical shift index study. Two-electrode voltage clamp techniques and MD simulations were used to study the impact of
disulfide bond deletion on the activities of the peptides at human neuronal nAChRs. All disulfide-deleted variants except
ImI[C2H,C8F] had reduced potency for inhibiting nAChRs. Our results suggest that the CI−CIII disulfide bond is important to
stabilize the secondary structure of α-conotoxins as well as their interaction with neuronal nAChR targets. Results from this study
enrich our understanding of the function of the CI−CIII disulfide bond and are useful in guiding future structural engineering of
the α-conotoxins.
■ INTRODUCTION
α-Conotoxins from themarine snail genusConus are inhibitors of
muscle and neuronal nicotinic acetylcholine receptors
(nAChRs).1−3 The majority of native α-conotoxins have two
internal disulfide cross-links between cysteines CI and CIII and
CII and CIV. The number of residues between CII and CIII (m)
and CIII and CIV (n) define different types of α-conotoxins, which
are noted as m/n (Figure 1).1−3
Three α-conotoxins, Vc1.1, RgIA, and AuIB, have been shown
to have a potent, long-lasting analgesic effect in rat models of
chronic neuropathic and visceral pain.4−8 Although these α-
conotoxins preferentially antagonize neuronal nAChRs, with
RgIA and Vc1.1 targeting the α9α10 nAChR subtype4 and AuIB
inhibiting the α3β4 nAChR subtype,9 the involvement of these
nAChRs in pain transmission pathways remains unclear.10 These
three conotoxins also potently inhibit high-voltage-activated
(HVA; N- and R-type) calcium channels via the G-protein-
coupled γ-aminobutyric acid B receptor (GABABR) in rat dorsal
root ganglion neurons, providing another explanation to their
analgesic properties.5,6 To date, Vc1.1 and AuIB have been
reported to target the GABABR, whereas the activity of BuIA and
ImI at GABABR is yet to be investigated. All four α-conotoxins
Vc1.1, BuIA, ImI, and AuIB antagonize different nAChR
subtypes, and therefore in the present study, the activity of the
four conopeptides was evaluated on the neuronal nAChRs.
Despite their pharmacological potential, the application of
conotoxins has been hindered by their short biological half-life,
intrinsic disulfide bond shuffling, susceptibility to enzymatic
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degradation, poor absorption, and limited oral availability.11
Consequently, these conotoxins have been subjected to chemical
modifications to improve the efficacy of synthesis and biological
properties.12
Figure 1. NMR solution structures and sequences of α-conotoxins Vc1.1 (green), BuIA (blue), ImI (red), and AuIB (magenta) and the sequences of
their disulfide-deleted analogues. (A) Vc1.1, (B) BuIA, (C) ImI, and (D) AuIB are small disulfide-rich (yellow) peptides belonging to the 4/7, 4/4, 4/3,
and 4/6 α-conotoxin subfamilies, respectively. The CI−CIII disulfide bond of the α-conotoxins is deleted by replacing the Cys residues with His at
position 2 and Phe at position 8. *m and n indicate the number of residues between CII−CIII and CIII−CIV disulfide bonds, respectively.
Figure 2. Structural comparison of the wild-type α-conotoxins Vc1.1, BuIA, ImI, and AuIB and their disulfide-deleted analogues from 100 ns MD
simulations. (A,D,G,J) rmsd for backbone Cα of the wild-type (black line) and mutant (red line) conotoxins. (B,C,E,F,H,I,K,L) Backbone conformation
of the peptides extracted from the last 50 ns MD trajectories with equal time intervals. ▼ indicates the time phase when rmsd significantly fluctuated.
Values of the Hα chemical shift deviation from the wild-type peptide are used to evaluate the mutational effect on the peptide secondary structure.
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Although the disulfide bridges are pivotal in stabilizing the
structure of conotoxins, they are inherently unstable under
reducing environments. Disulfide bond shuffling in conotoxins
can result in heterogeneous peptide conformations, therefore
increasing the production cost and concurrently lowering the
peptide synthesis efficiency. Additionally, compounds with
alternative disulfide connectivity typically have altered bio-
chemical properties.13,14 One strategy to prevent disulfide bond
shuffling of α-conotoxins is to replace one or both CI−CIII and
CII−CIV disulfide bonds with nonnatural amino acid cross-links,
such as lactam bridges,15 selenocysteines,16 dicarba bridges,17,18
cystathionine bridges,19 or dithiol amino acids.20 Replacement of
disulfide bridges of α-conotoxins by lactam or dicarba bridges
resulted in altered conformations and between 20- and 60-fold
decreased activity or binding at nAChRs.15,17,18 Other strategies
relying on selenocysteines, cystathionines, or dithiol amino acids
had less impact on the structure, and the resulting compounds
had similar or improved activity.16,19,20 Despite these successes,
nonnatural amino acids are not optimal for the development of
α-conotoxins as drugs because they cannot be produced
recombinantly and they increase the cost of synthetic
production. We have recently shown that an alternative strategy
is to replace disulfide bonds with tight-binding standard amino
acids, forming a hydrophobic mini-core.21 We showed that the
[C2H,C8F] modification to the CI−CIII bond of the cyclic
conotoxin Vc1.1 (cVc1.1) resulted in a nearly identical
conformation and a decreased activity of more than twofold at
α9α10 nAChR,21 contrasting with the complete loss of activity
displayed by the dicarba replacement of the same disulfide
bond.18 Therefore, [C2H,C8F] modification to the CI−CIII
bond could be an efficient strategy to simplify the structure of
the cyclic conotoxins. Then, a question arises regarding the
feasibility of the application of [C2H,C8F] modification to the
CI−CIII bond of the native α-conotoxins.
In this study, we investigated (i) the structure of 4/7(m/n)-
Vc1.1, 4/4-BuIA, 4/3-ImI, and 4/6-AuIB disulfide-deleted
[C2H,C8F] analogues, in which cysteine residues at positions
2 and 8 of the peptides are substituted with histidine and
phenylalanine residues, respectively (Figure 1), using molecular
dynamics (MD) simulation; (ii) the potency of Vc1.1-
[C2H,C8F] analogue at human (h)α9α10 and hα3β2 nAChRs,
BuIA[C2H,C8F] at hα3β2 and hα3β4 nAChRs, ImI[C2H,C8F]
at hα7 and hα9α10 nAChRs, and AuIB[C2H,C8F] at hα3β4
nAChRs expressed in Xenopus laevis oocytes; and (iii) the
molecular docking models of the above [C2H,C8F] conotoxin
analogues at their respective human nAChRs.
■ RESULTS AND DISCUSSION
Structural Impact of the Replacement of Disulfide
Bond CI−CIII. The backbone conformation of the [C2H,C8F]
conotoxin variants remained similar to that of their parent
peptide during MD simulation, but some transient instabilities
were observed. The backbone conformation of both Vc1.1-
[C2H,C8F] and Vc1.1 was very stable during MD simulations,
with the backbone root-mean-square deviation (rmsd) values
ranging from 0.5 to 1 Å (Figure 2A), suggesting that the mutant
and wild-type peptides might have similar backbone conforma-
tion (Figure 2B,C). The backbone conformation of AuIB
appeared to be also stable, with rmsd values ranging between
0.25 and 0.75 Å (Figure 2J). The substitution of both AuIB C2
and C8 resulted in a deviation of less than 1 Å for ∼70% of the
simulation, with short-lived metastable conformations charac-
terized by 1.7 Å rmsd from the parent peptide appearing twice
during the 100 ns simulation. This suggests a probably more
critical role of the CI−CIII disulfide bond in stabilizing the
structure of AuIB than that of Vc1.1.
Short-lived metastable conformations were also observed in
the simulations of BuIA, with 80% of explored conformations
being less than 1 Å rmsd from the nuclear magnetic resonance
(NMR) solution structure, and two short-lived periods where the
conformation was ∼1.2 Å rmsd (Figure 2D). The simulation of
BuIA suggests that the fold of some α-conotoxins might be
unstable in water, which is not completely surprising because
most peptides of similar size are disordered in solution. The
[C2H,C8F] substitution destabilized the fold of BuIA in the first
40 ns, as evidenced by the unstable rmsd values. These values
Figure 3. Superimposed Hα secondary chemical shifts of wild-type α-conotoxins Vc1.1, BuIA, ImI, and AuIB (black line) and their disulfide-deleted
analogues (red line). The correlation coefficients (R2 score) for (A) Vc1.1 vs Vc1.1[C2H,C8F], (B) BuIA vs BuIA[C2H,C8F], (C) ImI vs
ImI[C2H,C8F], and (D) AuIB vs AuIB[C2H,C8F] are 0.91, 0.23, 0.73, and 0.55, respectively.
ACS Omega Article
DOI: 10.1021/acsomega.7b00639
ACS Omega 2017, 2, 4621−4631
4623
were nevertheless below 1.5 Å and then stabilized at around 0.75
Å for nearly 50 ns, suggesting that the conformation at that time
could be as stable as the conformation of BuIA. The range of
conformations explored during the simulation remained similar
to those of the parent peptide (Figure 2E,F).
The MD simulation of ImI was not stable, with two apparent
metastable conformations characterized by rmsd values of 0.5
and 1.0 Å (Figure 2G). Similar to the other three peptides, the
replacement of the first cysteine resulted in some destabilization,
which can be seen in the greater fluctuation of the rmsd of the
variant compared to the parent peptide. The panel of
conformations adopted by ImI[C2H,C8F] was <1 Å rmsd for
70% of the simulation, and the range of conformations was
globally similar to those observed during ImI MD simulation
(Figure 2H,I).
MD simulations of the wild-type and variant conotoxins
indicated that the removal of the disulfide bond formed between
Cys2 and Cys8 might result in no conformational change for
Vc1.1 and ImI, whereas modest impact could be observed for
AuIB and BuIA, with 0.2 and 0.3 Å rmsd change, respectively.
For all peptides apart from Vc1.1, the removal of the disulfide
conformation was inferred to result in destabilization of the
native fold, with more frequent exploration of alternative
conformations. The smallest peptide without a disulfide bond
displaying a defined fold in solution is Trp cage, which has 20
amino acid residues.22 The α-conotoxins studied here are
noticeably smaller (12 and 15 residues), and their conforma-
tional stability despite their small size is attributed to their two
disulfide bond cross-links. It is therefore remarkable that the
present MD simulations suggest that some of these variants with
only one disulfide bond could still display a defined fold.
Structural differences between conotoxins are contributed by
their individual sequence of amino acids and more importantly
their innate disulfide frameworks. In comparison to Vc1.1, AuIB,
and BuIA, ImI has the shortest n loop and consequently the
shortest helix. This decreased secondary structure content
Figure 4. Activity of Vc1.1, BuIA, ImI, and AuIB and their disulfide-deleted analogues (10 μM) at human nAChR subtypes. Superimposed
representative ACh-evoked currents recorded from X. laevis oocytes expressing hα9α10 (A,E), hα3β2 (B,C), hα3β4 (D,G), and hα7 (F) nAChRs in the
absence (black trace) and presence (red trace) of 10 μMVc1.1 and Vc1.1[C2H,C8F] (A,B), BuIA and BuIA[C2H,C8F] (C,D), ImI and ImI[C2H,C8F]
(E,F), and AuIB and AuIB[C2H,C8F] (G).
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resulted in a lower stability of ImI compared to the other three
peptides, as evidenced by the fluctuations of rmsd. The lower
stability of ImI can also be attributed to the presence of only one
proline residue, whereas Vc1.1, AuIB, and BuIA have 2, 3, and 2
proline residues, respectively. Proline residues have a fixed φ
backbone dihedral angle, and they therefore contribute to
decreased peptide flexibility. Taken together, ImI has the least
rigid peptide backbone compared to Vc1.1, AuIB, and BuIA.
The Hα secondary chemical shifts of Vc1.1 and its disulfide-
deleted analogue are nearly identical, with a correlation
coefficient R2 of 0.91, demonstrating that the two peptides
have similar structures (Figure 3A). NMR spectrometry data
thus supported the results from MD simulations regarding the
conformational stability and similarity of Vc1.1 and Vc1.1-
[C2H,C8F]. By contrast, the removal of the disulfide bridge
greatly affected the structure of BuIA (R2 = 0.23), with significant
Hα secondary chemical shift deviation from the wild-type
peptide in the first half portion and also in the C-terminal tail of
the peptide (Figure 3B). Interestingly, the secondary shifts
indicate an increased α-helical content in the second half of the
peptide of disulfide-deleted BuIA. For ImI, minimal Hα
secondary chemical shift deviation (R2 = 0.73) was observed
between the wild-type and disulfide-deleted peptides (Figure
3C), indicating that their structures are similar, as predicted by
Figure 5. Inhibition of human nAChR subtypes by Vc1.1, BuIA, ImI, and AuIB and their disulfide-deleted analogues. The bar graph of the relative ACh-
evoked current amplitude mediated by hα9α10 (A,E), hα3β2 (B,C), hα3β4 (D,G), and hα7 (F) in the presence of 1, 10, and 30 μM Vc1.1 and
Vc1.1[C2H,C8F] (A,B), BuIA and BuIA[C2H,C8F] (C,D), ImI and ImI[C2H,C8F] (E,F), and AuIB and AuIB[C2H,C8F] (G). Whole-cell currents
mediated by hα9α10 and hα3β2 nAChRs were activated by 6 μMACh, whereas those mediated by hα7 and hα3β4 were activated by 100 and 300 μM
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the MD simulations. For AuIB, the Hα secondary chemical shifts
for positions 6, 7, 8, and 10 deviate between the wild-type and the
disulfide-deleted variant by 0.5 ppm, suggesting a small change of
conformation (Figure 3D). The Hα secondary chemical shifts
from positions 11 to 15 are more negative for the variant,
suggesting a helical structure. The deletion of the CI−CIII
disulfide bond of BuIA and AuIB resulted in higher rmsd values
during MD simulations and supported by NMR spectroscopy
analysis, which indicated that their C-terminus has an increased
helical content compared to the parent peptides.
Only Vc1.1[C2H,C8F] showed an overall Hα secondary
chemical shift R2 value of more than 0.9, suggesting that the
removal of the Cys residues at positions 2 and 8 essentially
maintains the peptide secondary structure. The secondary
structures of BuIA, ImI, and AuIB, however, are highly
dependent on the cysteine bond between residues Cys2 and
Cys8. Previously, we have demonstrated the involvement of
introduced residues, His2 in electrostatic interaction and Phe8 in
the formation of the peptide hydrophobic core, both important
in stabilizing the secondary structure of cVc1.1[C2H,C8F].21
Thus, here we assumed that the varying stability between
Vc1.1[C2H,C8F], ImI[C2H,C8F], and AuIB[C2H,C8F] is
primarily due to their sequence differences.
Figure 6.Molecular docking of wild-type α-conotoxins Vc1.1, BuIA, ImI, and AuIB and their disulfide-deleted analogues (orange)at homology models
of human nAChRs (the principal (+) subunit in green; the complementary (−) subunit in cyan). (A,B) Vc1.1 and Vc1.1[C2H,C8F] bound to the
α10(+)α9(−) binding site of hα9α10 nAChR. (D,E) BuIA and BuIA[C2H,C8F] bound to the α3(+)β2(−) binding site of hα3β2 nAChR. (G,H) ImI
and ImI[C2H,C8F] bound to the α10(+)α9(−) binding site of hα7 nAChR. (J,K) AuIB and AuIB[C2H,C8F] bound to the α3(+)β4(−) binding site of
hα3β4 nAChR. The dashed lines show the H bond formed between pairwise interacting residues of the conotoxins and nAChRs. (C,F,I,L) Opening
probability distribution for the C-loop of the human nAChRs for the wild-type α-conotoxin (blue) and the mutants (orange). The arrow indicates right
shift movement of the nAChR C-loop.
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The backbone root-mean-square fluctuation (RMSF) of the
wild-type peptide and its disulfide-deleted analogues was
calculated to evaluate their stability in solution (Figure S1).
Removal of the disulfide bond resulted in significant backbone
fluctuation for the first four residues of Vc1.1[C2H,C8F],
whereas the RMSF for residues between 5 and 16 is similar
between Vc1.1 and its disulfide-deleted analogue. Interestingly,
the backbone RMSF of BuIA is comparable to that of
BuIA[C2H,C8F], despite their large structural conformational
difference. In contrast to BuIA, the RMSF for AuIB[C2H,C8F] is
substantially larger than that of the wild-type. The backbone
RMSF for both the N- and C-termini of ImI[C2H,C8F] is larger
than that of the wild-type for positions 1−3 and 10−12.
Impaired Inhibitory Effect of Disulfide-Deleted α-
Conotoxin Analogues at Human nAChRs. Removal of the
CI−CIII disulfide bond of Vc1.1, BuIA, and AuIB (10 μM)
substantially reduced the ability of the peptides to inhibit
acetylcholine (ACh)-evoked currents of their respective human
nAChR targets expressed in X. laevis oocytes (see Figure 4).
Despite the high degree of secondary structural similarity
between Vc1.1 and Vc1.1[C2H,C8F], inhibition of hα9α10
nAChR by the [C2H,C8F] mutant was detected only at 30 μM,
with negligible activity at 1 and 10 μM (Figure 5A). Similarly,
there was minimal inhibition of hα3β2 nAChR by 1 and 10 μM
Vc1.1[C2H,C8F], and substantial inhibition was only observed
at 30 μM (Figure 5B). By contrast, wild-type Vc1.1 is a potent
inhibitor of hα9α10 and hα3β2 nAChRs, with complete
inhibition observed at 10 μM. Previously engineered
[C2H,C8F] mutant of cVc1.1 was reported to retain the
structural integrity of the wild-type counterpart but with only
twofold loss of potency at inhibiting hα9α10 nAChR.21 In this
study, we show dramatic loss of Vc1.1[C2H,C8F] activity at
hα9α10 nAChR, although it is structurally similar to Vc1.1,
suggesting that the CI−CIII disulfide bond may be directly
involved in the interaction between the peptide and the nAChR.
Arguably, the difference in potency between the cyclized and
linear [C2H,C8F] mutants could be due to the presence of the
short linker, joining the N- and C-termini of the cyclized peptide.
The linker was originally introduced as a scaffold to stabilize the
three-dimensional structure of cVc1.1, and it may have
inadvertently compensated the loss of cVc1.1[C2H,C8F]
potency.
Disulfide deletion of BuIA similarly resulted in a significant
loss of potency at hα3β2 and hα3β4 nAChRs (Figure 5C,D). For
both human nAChR subtypes, 1 μMBuIA inhibited >90% of the
ACh-evoked current amplitude compared to ∼70% at 30 μM
BuIA[C2H,C8F]. AuIB[C2H,C8F] exhibited no activity at
hα3β4 nAChR, with no inhibition of the ACh-evoked current
amplitude in the presence of 30 μM AuIB[C2H,C8F] (Figure
5G).
The potency of ImI[C2H,C8F] at inhibiting ACh-evoked
currents mediated by hα9α10 and hα7 nAChRs was also
reduced, albeit to a lesser extent compared to the [C2H,C8F]
mutants of Vc1.1, BuIA, and AuIB. Compared to ImI,
ImI[C2H,C8F] remains largely active at inhibiting both human
nAChR subtypes (Figure 5E,F), which is consistent with the
observed subtle secondary structural change between the two
peptides. Although the conformational shift of ImI[C2H,C8F] is
larger (R2 = 0.73) than that of Vc1.1[C2H,C8F] (R2 = 0.91), the
mutant ImI peptide retains comparable potency to ImI at 10 and
30 μM peptide concentrations tested, in inhibiting hα9α10 and
hα7 nAChRs. By contrast, only 30 μM Vc1.1[C2H,C8F] had
discernible inhibitory activity at both nAChRs. The concen-
tration-dependent activity of ImI and ImI[C2H,C8F] at the hα7
nAChR subtype was determined, giving a half-maximal inhibitory
concentration (IC50) of 497 ± 32 nM (as reported previously)
23
and 9.59 ± 0.62 μM, respectively (Figure S2).
Despite α-conotoxin disulfide-deleted analogues of Vc1.1, ImI,
and AuIB being structurally similar to their wild-type counter-
parts, functional screening of their potency at human nAChRs
revealed contradicting results. AuIB[C2H,C8F] did not inhibit
hα3β4 nAChR (up to 30 μM), whereas [C2H,C8F] analogues of
Vc1.1 and BuIA have significantly reduced potency at human
nAChR subtypes. By contrast, relatively minimal impact on the
activity of ImI[C2H,C8F] at hα9α10 and hα7 nAChRs was
observed.
In another study, oxidation of the first disulfide bond of ImI
was identified as more important for binding than that of the
second disulfide bond.24 A more recent study reported that
downsized α-conotoxins having only the first loop cyclized by the
CI−CIII disulfide bond were still active at nAChRs. By contrast,
cyclization of the second loop using the CII−CIV disulfide bond
resulted in inactive conotoxins.25 More generally, most attempts
at replacing only the first disulfide bond using nonnatural cross-
linking residues resulted in a significant decrease in
activity.15,17,18 An alternative strategy for simplifying the
structure of α-conotoxins with minimal impact on activity
could therefore be the substitution of the second disulfide bond,
which could be achieved using the methodology presented here.
Binding Mode of α-Conotoxins and Their [C2H,C8F]
Mutants at Human nAChR Principal Subunit C-Loop.MD
simulations on models of the α-conotoxin−nAChR complex
were performed to gain a better understanding on the interaction
between the peptides and their target human nAChRs. The
binding pocket for α-conotoxins at nAChRs is formed at the
extracellular interface between adjacent principal (+) α subunit
and complementary (−) α/β subunit. Specifically, (+) subunit
loops A−C and loops D−F of the (−) subunit contribute to α-
conotoxin recognition by nAChRs.
Our generated docking models revealed that for all four wild-
type α-conotoxins (Figure 6A,D,G,J), the CI−CIII disulfide bond
is buried in the binding site and formed direct contact with the
disulfide bond formed between residues Cys192 and Cys193 of
the (+) subunit C-loop. By contrast, less interaction was
observed between the [C2H,C8F] mutants and the nAChRs,
resulting in larger movement of the C-loop (Figure 6C,F,I,L).
The opening of the hα9α10 nAChR C-loop bound with
Vc1.1[C2H,C8F] and the opening of the hα3β4 nAChR C-
loop bound with AuIB[C2H,C8F] were significantly right shifted
to a comparable extent of ∼3 Å. The C-loop opening of the
AuIB[C2H,C8F]-bound hα3β4 nAChR was the most right
shifted, resulting in increased solvent exposure of the peptide and
consequently substantial loss of potency at inhibiting the
nAChR. By contrast, the opening of the hα3β2 nAChR C-
loop-bound BuIA[C2H,C8F] and the opening of the α7 nAChR
C-loop-bound ImI[C2H,C8F] were only slightly right shifted.
The weaker binding of Vc1.1[C2H,C8F] and AuIB-
[C2H,C8F] to their nAChR targets mainly resulted from the
solvent-semiexposed side chain of the introduced His2 residue
and the bulky benzyl side chain of the Phe8 residue. As a result,
Vc1.1[C2H,C8F] and AuIB[C2H,C8F] have fewer contacts
with the tip of the C-loop, which could be a contributing factor to
their reduced potency at inhibiting their target nAChRs despite
their minor secondary structure perturbation. The loss of
Vc1.1[C2H,C8F] potency can also be attributed to the absence
of hydrogen bond between peptide His12 and hα9α10 nAChR
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Glu195 residues because of the increased opening of the C-loop.
In addition, the loss of AuIB[C2H,C8F] potency can also be
attributed to the dramatic increase in backbone fluctuation,
decrease in backbone stability as well as conformational change
in the bound state.
On the other hand, the minor conformational change for the
C-loop of hα3β2 nAChR/BuIA[C2H,C8F] and the C-loop of
hα7 nAChR/ImI[C2H,C8F] might explain their relatively
smaller decrease in activity than that of Vc1.1[C2H,C8F] and
AuIB[C2H,C8F]. Loss of BuIA[C2H,C8F] activity at human
nAChRs can be attributed to the large local conformational
perturbation from BuIA, as evident from MD simulations and
Hα chemical shift analysis. Although the secondary structure of
BuIA[C2H,C8F] was most affected, the peptide still retained
some activity at inhibiting hα3β2 and hα3β4 nAChRs. The
relatively smaller loss of activity for BuIA[C2H,C8F] might
originate from the smaller conformational perturbation to the C-
loop and the comparable backbone RMSF to the wild-type. In
contrast to BuIA[C2H,C8F], the secondary structure of
ImI[C2H,C8F] is similar to that of ImI in both unbound and
bound states; therefore, the CI−CIII disulfide bond can be
postulated to have a minor influence on the structure and
inhibitory activity of ImI at hα9α10 and hα7 nAChRs.
Additionally, the bound-state rmsd of Vc1.1, BuIA, ImI, and
AuIB and their disulfide-deleted analogues was calculated to
qualitatively evaluate the influence of the conformational change
to their nAChR binding (Figure S3). In the bound state, the
backbone rmsd for Vc1.1[C2H,C8F] and ImI[C2H,C8F] is
similar to that of the wild-type, whereas the rmsd for
BuIA[C2H,C8F] and AuIB[C2H,C8F] is substantially larger
compared to that of the wild-type. Overall, these results are
consistent with MD simulations of the unbound state.
In summary, our results demonstrate that the CI−CIII bond of
the α-conotoxins regardless of their cysteine framework
classification has a critical role of not only in stabilizing their
secondary structure and maintaining their stability but also in
their binding to multiple human nAChRs. Most importantly, we
provide evidence to support the fact that this disulfide bond is not
just a redundant feature but has been selectively conserved within
the α-conotoxins as a structural scaffold for them to be
biologically active.
■ METHODS
Homology Modeling. Models of Vc1.1/Vc1.1[C2H,C8F]-
bound human α9α10 nAChRs, ImI/ImI[C2H,C8F]-bound
human α9α10 and α7 nAChRs, BuIA/BuIA[C2H,C8F]-bound
human α3β4 nAChRs and α3β2 nAChRs, and AuIB/AuIB-
[C2H,C8F]-bound human α3β4 nAChRs were built using
Modeller (version 9v12), as described previously.26 The
sequences of human α1, α3, α4, α6, α7, α9, α10, β2, β3, and
β4 nAChR subunits were retrieved from the UniProt database.27
The crystal structures ofAplysia californica AChBP (ACh binding
protein) in complex with α-conotoxin PnIA[A10L,D14K] (PDB
code 2BR8)28 and the extracellular domains of mouse α1 (PDB
code 2QC1)29 and human α9 (PDB code 4D01)30 nAChR
subunits were used as templates to build 200 models of each α-
conotoxin/nAChR complexes. Models with the lowest discrete
optimized protein energy score31 were selected for further
structural refinement using MD simulations.
MD Simulations of α-Conotoxins. The designs of α-
conotoxins Vc1.1, BuIA, ImI, and AuIB tested in this study are
summarized in Figure 1. Their structures were modeled by
substituting the corresponding residues in the structure of α-
conotoxins (Vc1.1 PDB code 2H8S,32 BuIA PDB code 2I28,33
ImI PDB code 2C9T,34 and AuIB PDB code 1MXN35) using
Modeller (version 9v12).36,37
The protonation states of α-conotoxin His, Asp, and Glu
residues were predicted using the PropKa 3.1 method.38 The
models and the first NMR structure were minimized and refined
usingMD simulations performed with the Amber 14 package and
ff14SB force field.39,40 The peptides were solvated in a truncated
octahedral TIP3P water box containing ∼3000 water molecules.
Sodium ions were added to neutralize the systems. The systems
were first minimized with 3000 steps of steepest descent and then
3000 steps of conjugate gradient with the solute restrained to
their position by a harmonic force of 100 kcal/mol·Å2. A second
minimization was then performed but with all position restraints
withdrawn. The systems were then gradually heated up from 50
to 300 K in the NVT ensemble over 100 ps with the solute
restrained to their position using a 5 kcal/mol·Å2 harmonic force
potential. The MD simulations were then carried out in the NPT
ensemble, and the position restraints were gradually removed
over 100 ps. The production runs were conducted over 100 ns
simulation time with pressure coupling set at 1 atm and a
constant temperature of 300 K. The MD simulations used a time
step of 2 fs, and all bonds involving hydrogen atoms were
maintained to their standard length using the SHAKE
algorithm.41 The particle mesh Ewald method was used to
model long-range electrostatic interactions.42 MD trajectories
were analyzed using visual molecular dynamics,43 and molecules
were drawn using PyMol (Schrödinger, LLC). Procedures and
parameters set up are the same for the MD simulation of the α-
conotoxin-bound nAChRs.
α-Conotoxin Synthesis. All α-conotoxins used in this study
were assembled on the Rink amidemethylbenzhydrylamine resin
using solid-phase peptide synthesis with a neutralization/2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophos-
phate activation procedure for Fmoc (N-(9-fluorenyl)-
methoxycarbonyl) chemistry as described previously.44 Cleavage
was achieved by treatment with a mixture of trifluoroacetic acid,
phenol, water, and triisopropylsilane as scavengers in the ratio of
88:5:5:2, at room temperature (20−25 °C) for 2 h. Trifluoro-
acetic acid was evaporated at low pressure in a rotary evaporator.
Peptides were precipitated with ice-cold ether, filtered, dissolved
in 50% buffer A/B (buffer A consists of 99.95% H2O/0.05%
trifluoroacetic acid and buffer B consists of 90% CH3CN/10%
H2O/0.045% trifluoroacetic acid), and lyophilized. Crude
peptides were purified by reversed-phase high-performance
liquid chromatography (RP-HPLC) on a Phenomenex C18
column using a gradient of 0−100% methanol for 80 min, with
the eluent monitored at 214/280 nm. Electrospray mass
spectrometry confirmed the molecular mass of the peptides
before they were pooled and lyophilized for oxidation. The
cysteines in the peptides were oxidized in 0.1 M NH4HCO3 (pH
8−8.5) at a concentration of 1 mg/mL, and the mixture was
stirred at room temperature for 48 h. Owing to its poor solubility
in water, the reduced ImI[C2H,C8F] peptide was dissolved in
20% CH3CN/80% H2O prior to adding NH4HCO3. The
oxidized peptides were then purified by RP-HPLC using a
gradient of 0−40% buffer B over 40 min. Analytical RP-HPLC
and electrospray mass spectrometry were used to confirm the
purity and molecular mass of the synthesized peptides.
NMR Study of α-Conotoxin Mutants.NMR spectra of the
mutants were recorded on a Bruker AVANCE 500 MHz
spectrometer. Samples were dissolved in 90% H2O/10% D2O at
pH 4.25 at a concentration of 2 mg/mL. Total correction
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spectroscopy (TOCSY) and nuclear Overhauser enhancement
spectroscopy (NOESY) data were collected at 290 K. The Hα
chemical shifts were assigned by analyzing the TOCSY and
NOESY spectra using CcpNmr software.45
In Vitro cRNA Synthesis. Plasmid pMXT construct of the
human α7 nAChR subunit was linearized with BamHI, and
plasmid pT7TS constructs of human α3, α9, α10, β2, and β4
nAChR subunits were linearized with XbaI restriction enzymes
(NEB, Ipswich, MA) for in vitro cRNA transcription using SP6
(hα7) and T7 (hα3, α9, α10, β2, and β4) mMessage mMachine
transcription kits (AMBION, Foster City, CA).
Oocyte Preparation and Microinjection. All procedures
were approved by the University of Sydney Animal Ethics
Committee. Stage V−VI oocytes were obtained from X. laevis,
defolliculated with 1.5 mg/mL collagenase type II (Worthington
Biochemical Corp., Lakewood, NJ) at room temperature for 1−2
h in OR-2 solution containing (in mM) 82.5 NaCl, 2 KCl, 1
MgCl2, and 5HEPES at pH 7.4. The oocytes were injected with 5
ng cRNA for hα3β2, hα3β4, and hα7 nAChRs or 35 ng cRNA for
hα9α10 nAChR (concentration confirmed spectrophotometri-
cally and by gel electrophoresis) using glass pipettes pulled from
glass capillaries (3-000-203 GX, Drummond Scientific Co.,
Broomall, PA). The oocytes were incubated at 18 °C in sterile
ND96 solution composed of (in mM) 96NaCl, 2 KCl, 1 CaCl2, 1
MgCl2, and 5 HEPES at pH 7.4, supplemented with 5% FBS, 50
mg/L gentamicin (GIBCO, Grand Island, NY), and 10 000 U/
mL penicillin−streptomycin (GIBCO, Grand Island, NY).
Oocyte Two-Electrode Voltage Clamp Recording and
Data Analysis. Electrophysiological recordings were carried out
2−5 days post-cRNA microinjection. Two-electrode voltage
clamp recordings of X. laevis oocytes expressing human nAChRs
were performed at room temperature (21−24 °C) using a
GeneClamp 500B amplifier and pCLAMP9 software interface
(Molecular Devices, Sunnyvale, CA) at a holding potential of
−80 mV. Voltage-recording and current-injecting electrodes
were pulled from GC150T-7.5 borosilicate glass (Harvard
Apparatus, Holliston, MA) and filled with 3 M KCl, giving
resistances of 0.3−1 MΩ.
The oocytes were perfused with ND96 solution using a
continuous Legato 270 push/pull syringe pump perfusion
system (KD Scientific, Holliston, MA) at a rate of 2 mL/min.
For oocytes expressing hα9α10 nAChRs, 50 nL of 50 mM
BAPTA was injected using a glass pipette 1 h before recording
and perfused with ND115 solution containing (in mM) 115
NaCl, 2.5 KCl, 1.8 CaCl2, and 10 HEPES at pH 7.4. Owing to the
Ca2+ permeability of hα9α10 nAChRs, BAPTA injection was
carried out to prevent the activation of endogenous calcium-
activated chloride channels in X. laevis oocytes.
Initially, oocytes were briefly washed with bath solution
(ND96 or ND115) followed by three applications of ACh at half-
maximal excitatory concentration (EC50) of 6 μM for hα9α10
and hα3β2, 100 μM for hα7, and 300 μM for hα3β4 nAChRs.
The oocytes were washed with bath solution for 3 min between
ACh applications. The oocytes were incubated with peptides for
5 min with the perfusion system turned off, followed by
coapplication of ACh and peptide with flowing bath solution. All
peptide solutions were prepared inND96/ND115 + 0.1% bovine
serum albumin. Peak current amplitudes before (ACh alone) and
after (ACh + peptide) peptide incubation were measured using
Clampfit software (Molecular Devices, Sunnyvale, CA, USA)
where the ratio of ACh + peptide-evoked current amplitude to
ACh alone-evoked current amplitude was used to assess the
activity of the peptides at human nAChRs. All electro-
physiological data were pooled (n = 5 to 16) and represent
mean ± standard error of the mean (SEM). Data sets were
compared using an unpaired Student’s t-test. Differences were
regarded statistically significant when p < 0.05. The IC50 was
determined from the concentration−response curve fitted to a
nonlinear regression function and reported with error of the fit.
Data analysis was performed using GraphPad Prism 5 (Graph-
Pad Software, La Jolla, CA).
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